Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;77(6):421-30.
doi: 10.1111/j.1747-0285.2011.01108.x. Epub 2011 Apr 27.

Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor

Affiliations

Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor

Susan Keay et al. Chem Biol Drug Des. 2011 Jun.

Abstract

Interstitial cystitis/painful bladder syndrome is a chronic bladder disorder with epithelial thinning or ulceration, pain, urinary frequency and urgency, for which there is no reliably effective therapy. We previously reported that interstitial cystitis/painful bladder syndrome bladder epithelial cells make a glycopeptide antiproliferative factor or 'APF' (Neu5Acα2-3Galβ1-3GalNAcα-O-TVPAAVVVA) that induces abnormalities in normal cells similar to those in interstitial cystitis/painful bladder syndrome cells in vitro, including decreased proliferation, decreased tight junction formation, and increased paracellular permeability. We screened inactive APF derivatives for their ability to block antiproliferative activity of asialylated-APF ('as-APF') in normal bladder cells and determined the ability of as-APF-blocking derivatives to normalize tight junction protein expression, paracellular permeability, and/or proliferation of interstitial cystitis/painful bladder syndrome cells. Only two of these derivatives [Galβ1-3GalNAcα-O-TV-(d-pipecolic acid)-AAVVVA and Galβ1-3GalNAcα-O-TV-(d-proline)-AAVVVA] blocked as-APF antiproliferative activity in normal cells (p < 0.001 for both). Both of these antagonists also 1) significantly increased mRNA expression of ZO-1, occludin, and claudins 1, 4, 8, and 12 in interstitial cystitis/painful bladder syndrome cells by qRT-PCR; 2) normalized interstitial cystitis/painful bladder syndrome epithelial cell tight junction protein expression and tight junction formation by confocal immunofluorescence microscopy; and 3) decreased paracellular permeability of (14) C-mannitol and (3) H-inulin between confluent interstitial cystitis/painful bladder syndrome epithelial cells on Transwell plates, suggesting that these potent APF antagonists may be useful for the development as interstitial cystitis/painful bladder syndrome therapies.

PubMed Disclaimer

Conflict of interest statement

None of the authors has a conflict of interest related to the work described in this manuscript.

Figures

Figure 1
Figure 1. Structures of as-APF, d-proline as-APF, and d-pipecolic acid as-APF derivatives
Figure 2
Figure 2. Antiproliferative activity of as-APF, d-proline as-APF, and d-pipecolic acid as-APF derivatives in normal bladder epithelial cell explant cultures
Explanted normal bladder epithelial cells were treated with varying concentrations of as-APF (■), inactive control peptide (□), d-proline as-APF (▼), or d-pipecolic acid as-APF (○) for 48 hours prior to determination of 3H-thymidine incorporation. Assay was performed in triplicate twice; data are expressed as percent inhibition of thymidine incorporation compared to control cells incubated with medium alone +/- standard deviation.
Figure 3
Figure 3. Blocking of as-APF activity by d-proline as-APF and d-pipecolic acid as-APF in normal bladder epithelial cells
Explanted normal bladder epithelial cells were preincubated with varying concentrations of d-proline as-APF (■) or d-pipecolic acid as-APF (○) for 1.5 hours at 37°C, after which 125 nM as-APF was added to the medium; cell proliferation was assessed by 3H-thymidine incorporation 48 hours later. The assay was performed in triplicate twice; data are expressed as percent inhibition of thymidine incorporation compared to control cells incubated with medium alone +/- standard deviation.
Figure 4
Figure 4. Stimulation of IC/PBS cell proliferation by d-proline as-APF and d-pipecolic acid as-APF
Explanted cells from 3 IC/PBS donors were treated with varying concentrations of d-proline as-APF (■) or d-pipecolic acid as-APF (○); controls were incubated with culture medium alone (Δ). Cell proliferation was assessed by 3H-thymidine incorporation 48 hours later. The assay was performed in triplicate twice for each donor, and data points combined for all donors; data are expressed as counts per minute (CPM) +/- standard error of the mean.
Figure 5
Figure 5. RT-PCR analysis of tight junction protein mRNA expression in IC/PBS cells following treatment with d-proline as-APF or d-pipecolic acid as-APF
Explanted cells from IC/PBS donors were fed and treated with 2.5 μM d-proline as-APF (□), d-pipecolic acid as-APF ( formula image), inactive peptide ( formula image), or diluent control (■) twice weekly, and RNA was extracted at 9, 16, 23 and 30 days for qRT-PCR. By day 16, both APF derivatives were able to significantly (p < .05) stimulate tight junction protein expression in IC/PBS cells in vitro resulting in levels similar to those seen in bladder cells from age- and gender-matched normal donors ( formula image). PCR was performed in duplicate on three separate occasions for each sample; data are expressed as mean +/- standard error of the mean. (Data shown from experiment with the same IC/PBS cell donor treated simultaneously with either d-pipecolic acid as-APF or d-proline as-APF; d-proline as-APF was tested on cells from a total of 4 IC/PBS donors, with similar results)
Figure 6
Figure 6. Immunofluorescence confocal microscopy of IC/PBS cell explants treated with d-pipecolic acid as-APF, d-proline as-APF, or vehicle (PBS) alone for 9 days
Explanted cells from an IC/PBS donor were treated with 2.5 μM d-proline as-APF, d-pipecolic acid as-APF, or diluent (PBS) control twice weekly. On day 9, cells were fixed with acetone/ethanol and incubated with FITC-labeled anti-ZO-1 antibody, or primary antibodies against claudin or occludin proteins followed by FITC-labeled secondary antibodies. Images were obtained on a Zeiss LSM510 confocal laser scanning microscope. (Figure is representative of three separate experiments using cells from 3 IC/PBS donors)
Figure 7
Figure 7. Decreased paracellular permeability of IC/PBS cells by d-proline as-APF
Paracellular flux of [3H]-inulin (molecular weight: 5,200) or [14C]-mannitol (molecular weight: 184) was measured in IC/PBS cells cultured on Transwell membranes and treated with 2.5 μM d-proline as-APF (□), inactive peptide control ( formula image), diluent control (■), or calcium free medium ( formula image) for 16 days prior to incubation with tracer. Data are expressed as mean percent of the radioactivity applied to the apical medium that was recovered in the basal medium at 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs +/- standard deviation. (Data shown from 4 experiments using cells from 4 different IC/PBS donors).
Figure 8
Figure 8. Decreased paracellular permeability of IC/PBS cells by d-pipecolic acid as-APF
Paracellular flux of [3H]-inulin (molecular weight: 5,200) or [14C]-mannitol (molecular weight: 184) was measured in IC/PBS cells cultured on Transwell membranes and treated with 2.5 μM d-pipecolic acid as-APF (□), inactive peptide control ( formula image), diluent control (■), or calcium free medium ( formula image) for 16 days prior to incubation with tracer. Data are expressed as mean percent of the radioactivity applied to the apical medium that was recovered in the basal medium at 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs +/- standard deviation. (Data shown from 3 experiments using cells from 3 different IC/PBS donors).

Comment in

Similar articles

Cited by

References

    1. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143:1118–1124. - PubMed
    1. Skoluda D, Wegner K, Lemmel EM. Critical Notes: Respective immune pathogenesis of interstitial cystitis. (article in German) Urologe A. 1974;13:15–23. - PubMed
    1. Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang LP, Hardy C, Brensinger C, Matthews YL, Abele ST, Kusek JW, Nyberg LM. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the Interstitial Cystitis Database Study Group. Urology. 2001;57:67–81. - PubMed
    1. Lavelle J, Meyers S, Ramage R, Bastacky S, Doty D, Apodaca G, Zeidel ML. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am J Physiol Renal Physiol. 2002;283:F242–F253. - PubMed
    1. Acharya P, Beckel J, Ruiz WG, Wang E, Rojas R, Birder L, Apodaca G. Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epithelium. Am J Physiol. 2004;287:F305–F318. - PubMed

Publication types

MeSH terms